SEOUL, South Korea, May 14, 2026 /WiredBusiness/ – PharmaResearch Co., Ltd., a South Korean company specializing in regenerative medical technologies, has successfully completed a key Western European roadshow for its flagship product, REJURAN. The roadshow spanned five distinct markets, including the Benelux countries (Belgium, Netherlands, Luxembourg), the United Kingdom, and Switzerland, reflecting robust industry engagement with the company’s innovative regenerative medicine solutions.

PharmaResearch is focused on developing biotechnological advancements that support tissue regeneration and healing, positioning REJURAN as a pioneering offering in this sector. The company’s recent European roadshow was aimed at deepening market presence and fostering strategic partnerships in Western Europe as part of a carefully staged international growth strategy.

During the tour, PharmaResearch showcased REJURAN’s unique regenerative properties driving a strong interest among healthcare providers, biomedical enterprises, and investment stakeholders across these advanced markets. The roadshow served as a platform to engage with leaders in the regenerative medicine community, provide detailed clinical and commercial data, and discuss collaborative opportunities aimed at expanding REJURAN’s footprint in European markets.

REJURAN is recognized for its innovative use of polynucleotides to stimulate tissue repair processes, a breakthrough technology that has garnered significant attention for its clinical efficacy and potential applications in various regenerative therapies. PharmaResearch’s high-touch engagement approach during the roadshow has laid the groundwork for upcoming regulatory milestones, commercialization partnerships, and increased investment prospects within the region.

Executives at PharmaResearch emphasized that the positive reception across these diverse European healthcare ecosystems validates their phased approach to scaling REJURAN internationally. The company is leveraging insights gained during the roadshow to tailor commercialization strategies and address regulatory and reimbursement frameworks specific to each country.

This strategic engagement aligns with broader industry trends whereby South Korean biotech firms are accelerating global expansion to meet rising demand for next-generation regenerative therapies. PharmaResearch aims to build upon this momentum by incorporating feedback from European clinical and commercial stakeholders to optimize product offerings and support infrastructure development.

The successful completion of the Western Europe roadshow positions PharmaResearch to enhance its collaborative network across key European markets, facilitating faster adoption of REJURAN and integration into advanced healthcare settings. This milestone represents a critical step in PharmaResearch’s journey as a global biotech innovator, bridging cutting-edge regenerative medical technology from South Korea to the broader international stage.

For additional information on PharmaResearch’s initiatives and REJURAN’s evolving portfolio, the company will be providing ongoing updates in the coming months as regulatory progress and market expansion efforts advance.